Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. 08:34:11 2024-09-16 am EDT 5-day change 1st Jan Change
6,357.45 INR -0.14% Intraday chart for Alkem Laboratories Limited +1.43% +22.20%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks CI
Alkem Laboratories Limited Receives Orders Passed by Statutory Authority Under the Goods and Services Tax Act, 2017 CI
Alkem Laboratories Limited Receives an Order from Deputy Commissioner of Revenue, Large Taxpayer Unit, Kolkata, West Bengal CI
Alkem Laboratories Limited Receives an Order from Assistant Commissioner ­ Sector and Assistant Commissioner of GST & Central Excise, Ponneri Division CI
Alkem Laboratories Limited Receives an Order from Deputy Commissioner of State Tax Raipur Division-2, Chhattisgarh CI
KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies CI
Nomura Adjusts Alkem Laboratories' Price Target to INR6,061 From INR5,605, Keeps at Neutral MT
Jefferies Adjusts Alkem Laboratories' Price Target to INR5,080 From INR4,200, Keeps at Underperform MT
Alkem Laboratories' Fiscal Q1 Consolidated Net Profit Rises MT
Transcript : Alkem Laboratories Limited, Q1 2025 Earnings Call, Aug 09, 2024
Alkem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
Alkem Laboratories Limited Receives an Order-In-Appeal Passed by Statutory Authority Under the Goods and Services Tax Act, 2017 CI
Alkem Laboratories Limited Receives Order-In-Appeal Passed by Statutory Authority Under the Goods and Services Tax Act, 2017 CI
Alkem Laboratories Sets Up New Therapeutics Unit MT
Jefferies Forecasts Strong Fiscal Q1 for Indian Pharmaceuticals MT
Alkem Laboratories Limited Announces Change in Management CI
Alkem Laboratories Gets 'Voluntary Action Indicated' for Baddi, India Facility; Shares Jump 4% MT
Alkem Laboratories Limited Announces Resignation of Dheeraj Sharma as an Independent Director CI
Alkem Laboratories Limited Receives an Order-In-Appeal Passed by Joint Commissioner (Appeals-II), Hyderabad Commissionerate, Telangana CI
Alkem Laboratories to Invest INR300 Million in HaystackAnalytics MT
Alkem Laboratories' Consolidated Profit Soars in Fiscal Q4; Shares Slump 6% MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,200 From INR4,470, Keeps at Underperform MT
Transcript : Alkem Laboratories Limited, Q4 2024 Earnings Call, May 29, 2024
Alkem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024 CI
Chart Alkem Laboratories Limited
More charts
Logo Alkem Laboratories Limited
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
Employees
17,432
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
21
Last Close Price
6,357.45INR
Average target price
5,583.24INR
Spread / Average Target
-12.18%
Consensus
  1. Stock Market
  2. Equities
  3. ALKEM Stock
  4. News Alkem Laboratories Limited
  5. Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW